Extract
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial lung diseases (ILDs) and carries a poor prognosis. The recent therapeutic achievements have changed the management of the disease [1, 2] and increased the need for health economy evaluations. However, only a few studies have examined the economic consequences of IPF [3, 4]. The aim of the present study was: 1) to evaluate the health economic aspects of IPF in well-characterised patients diagnosed in accordance with the current evidence-based guidelines before the introduction of antifibrotic therapy [5]; and 2) to compare the health-related costs of IPF and matched controls from the general population using prospectively collected data from population-based medical databases in the predominantly tax-financed Danish healthcare system.
Abstract
When a patient is diagnosed with IPF, the net health costs increase from €2753 to €21 184 per year even without the cost of antifibrotic treatment. Inpatient treatment accounts for the main part of the expenses http://ow.ly/dSsn30jEx0p
Footnotes
Conflict of interest: E. Bendstrup has received lecture fees from Intermune, Roche and Boehringer Ingelheim and has participated in four advisory board meetings during the last 5 years. Her hospital has received an unrestricted grant from both Roche and Boehringer Ingelheim.
Support statement: This article was funded by F. Hoffman-La Roche (unrestricted grant from Intermune). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received April 4, 2017.
- Accepted April 19, 2018.
- Copyright ©ERS 2018
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.